In a significant ruling, the Bombay High Court has restrained Ahmedabad-based Meghmani Lifesciences from using the trademark 'Esiraft' for its products. This decision comes after Sun Pharmaceutical Industries, led by Dilip Sanghvi, filed a complaint alleging that 'Esiraft' infringes on its registered trademark 'Raciraft'. The court noted that the potential for confusion exists due to the phonetic and visual similarities between the two names. The division bench, comprising justices Bharati Dangre and Manjusha Deshpande, stated that the average consumer might be misled by the similarities, particularly given the nuances in pronunciation. Prior to this ruling, a single judge had vacated an earlier injunction that had been granted in April 2025. Sun Pharma's legal representative, advocate Hiren Kamod, argued that the differences in capitalization do not sufficiently distinguish the two marks.